Wide Ranks

MBX

MBX Biosciences, Inc.

20.97

Top Statistics
Market Cap 700 M Forward PE -9.19 Revenue Growth 0.00 %
Current Ratio 25.75 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -7.14 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 277 M Total Cash Per Share 8.29 Total Debt 210000
Total Debt To Equity 0.0770 Current Ratio 25.75 Book Value Per Share 8.13
All Measures
Short Ratio 389.00 % Message Board Id finmb_613097171 Shares Short Prior Month 311843
City Carmel Uuid a066c197-b79d-33dd-be3a-0bcc20467a16 Previous Close 19.83
First Trade Date Epoch Utc 1 B Book Value 8.13 Total Debt 210000
Volume 118700 Price To Book 2.58 Fifty Two Week Low 15.31
Total Cash Per Share 8.29 Shares Short Previous Month Date 1 B Target Median Price 37.50
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 37.25
Net Income To Common -55179000 Ask 21.28 Implied Shares Outstanding 33 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 139720
Average Volume10days 139720 Total Cash 277 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0324 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 19.83 Target Low Price 30.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 22.09 Open 20.13
Dividend Yield 0.00 % State IN Time Zone Short Name EST
Trailing Eps -1.65 Day Low 20.13 Address1 11711 N. Meridian Street
Shares Outstanding 33 M Price Hint 2 Target High Price 44.00
Website https://mbxbio.com 52 Week Change -0.1133 Average Volume 154350
Forward Eps -2.33 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 2545.10 % Is_sp_500 False Regular Market Day High 22.50
Profit Margins 0.00 % Debt To Equity 0.0770 Fifty Two Week High 27.50
Day High 22.50 Shares Short 350718 Regular Market Open 20.13
Industry Key biotechnology Bid 20.58 Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0103 Operating Cashflow -49790000
Currency USD Time Zone Full Name America/New_York Market Cap 700 M
Is_nasdaq_100 False Zip 46032 Quote Type EQUITY
Industry Biotechnology Long Name MBX Biosciences, Inc. Regular Market Day Low 20.13
Held Percent Institutions 0.9061 Current Price 20.97 Address2 Suite 300
Enterprise To Ebitda -7.14 Financial Currency USD Current Ratio 25.75
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 13 M Two Hundred Day Average 22.08 Enterprise Value 423 M
Forward PE -9.19 Regular Market Volume 118700 Ebitda -59348000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.

The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.

In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities.

The company was founded in 2018 and is based in Carmel, Indiana.